Volume 15, Number 5—May 2009
Research
CTX-M β-Lactamases in Escherichia coli from Community-acquired Urinary Tract Infections, Cambodia
Etienne Ruppé
, Sopheak Hem, Sovannarith Lath, Valérie Gautier, Frédéric Ariey, Jean-Louis Sarthou, Didier Monchy, and Guillaume Arlet
, Sopheak Hem, Sovannarith Lath, Valérie Gautier, Frédéric Ariey, Jean-Louis Sarthou, Didier Monchy, and Guillaume ArletTable 2
Resistance to antimicrobial agents among ESBL-positive and ESBL-negative Escherichia coli, Cambodia, 2004–2005*
| Antimicrobial agent | Resistance ratios, % (no. resistant strains) |
p value | ||
|---|---|---|---|---|
| ESBL+, n = 34 | ESBL–, n = 59 | Total, n = 93 | ||
| Fluoroquinolones | 94 (32) | 53 (31) | 68 (63) | <0.001 |
| Cotrimoxazole | 85 (29) | 69 (41) | 75 (70) | 0.06 |
| Aminoglycosides | 65 (22) | 27 (16) | 42 (39) | <0.01 |
| Co-amoxiclav | 94 (32) | 19 (11) | 46 (43) | <0.001 |
| Cefoxitin | 41 (13) | 11 (7) | 22 (20) | <0.001 |
| Nitrofurantoin | 0 | 0 | 0 | NS |
| Fosfomycin | 0 | 0 | 0 | NS |
*ESBL, extended-spectrum β-lactamase; NS, not significant.
